A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults

Journal of Infectious Diseases

Volumn 202, Issue 7, 2010, Pages 1114-1125

  Crum Cianflone, Nancy F ^a,c   Hullsiek, Katherine Huppler ^a,d   Roediger, Mollie ^a,d   Ganesan, Anuradha ^a,b   Patel, Sugat ^e   Landrum, Michael L ^a,f   Weintrob, Amy ^a,b   Agan, Brian K ^a   Medina, Sheila ^a,c   Rahkola, Jeremy ^g   Hale, Braden R ^a,c   Janoff, Edward N ^g,h   Banks, Susan ⁱ   Barahona, Irma ⁱ   Bavaro, Mary ⁱ   Brandt, Carolyn ⁱ   Chun, Helen ⁱ   Decker, Cathy ⁱ   Eggleston, Conner ⁱ   Ferguson, Tomas ⁱ   Fraser, Susan ⁱ   Hawkes, Cliff ⁱ   Johnson, Arthur ⁱ   Johnson, Erica ⁱ   Lifson, Alan ⁱ   Macalino, Grace ⁱ   Maguire, Jason ⁱ   Merritt, Scott ⁱ   Morse, Christie ⁱ   O'Connell, Robert ⁱ   Okulicz, Jason ⁱ   Peel, Sheila ⁱ   Polis, Michael ⁱ   Powers, John ⁱ   Ressner, Roseanne ⁱ   Tasker, Sybil ⁱ   Tramont, Edmund ⁱ   Wallace, Mark ⁱ   Whitman, Timothy ⁱ   Wortmann, Glenn ⁱ   Zapor, Michael ⁱ   more..

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^f SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ Denver Veterans Affairs Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE; VIRUS RNA; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; BACTERIUM ANTIBODY; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVACCINATION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VIRUS ENCEPHALITIS; WESTERN BLOTTING; ADOLESCENT; BLOOD; COMPARATIVE STUDY; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956942670     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656147     Document Type: Article

References (35)

1. Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992; 117:314-24.
2. Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006; 20:437-44.
3. Frankel RE, Virata M, Hardalo C, Altice FL, Friedland G. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. Clin Infect Dis 1996; 23:577-84.
4. Hibbs JR, Douglas JM Jr, Judson FN, McGill WL, Rietmeijer CA, Janoff EN. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994. Clin Infect Dis 1997; 25:195-9.
5. McEllistrem MC, Mendelsohn AB, Pass MA, et al. Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection. J Infect Dis 2002; 185:1364-8.
6. Jordano Q, Falcó V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623-8.
7. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58(RR-4):1-207.
8. Hausdorff W, Bryant J, Paradiso P, Siber G. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30:100-21.
9. Flannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 2004; 291:2197-203.
10. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006; 295:1668-74.
11. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46.
12. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51.
13. Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:2322-6.
14. Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009; 48:1392-401.
15. Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003; 101:831-6.
16. Kumar D, Chen MH, Welsh B, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007; 45:1576-82.
17. Madhi SA, Klugman KP, Kuwanda L, Cutland C, Käyhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009; 199:1168-76.
18. King JC Jr, Vink PE, Farley JJ, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15:192-6.
19. Lesprit P, Pédrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425-34. (Pubitemid 350145174)
20. Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20:545-53.
21. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2000; 19:886-94.
22. Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Revaccination with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34:813-21.
23. Division of AIDS table for grading the severity of adult and pediatric adverse events. Version 1.0. December 2004. http://rsc.tech-res.com/ safetyandpharmacovigilance/. Accessed on 20 August 2010.
24. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996; 173:83-90.
25. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22.
26. Miiro G, Kayhty H, Watera C, et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005; 192:1801-5.
27. Colino J, Chattopadhyay G, Sen G, et al. Parameters underlying distinct T cell-dependent polysaccharide-specific IgG responses to an intact gram-positive bacterium versus a soluble conjugate vaccine. J Immunol 2009; 183:1551-9.
28. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471-84.
29. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198: 1019-27.
30. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008; 47:1328-38.
31. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49:1318-25.
32. Bennett NM, Buffington J, LaForce FM. Pneumococcal bacteremia in Monroe County, New York. Am J Public Health 1992; 82:1513-6.
33. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160:2633-8.
34. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106-11. (Pubitemid 30364659)
35. Amendola A, Tanzi E, Zappa A, et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine 2002; 20:3720-4. (Pubitemid 35223401)